Hectic PR and damage control as EpiPen, insurers and Trump make news
Hours after the PEOTUS lambasted pharma, one CEO countered the criticism on Twitter. Meanwhile, CVS and Cigna have taken action they contend will ease costly burdens for consumers.
Communicators and crisis PR pros from several sectors—and politics—are angling to promote brands and, in some cases, downplay headlines.
News broke Thursday morning that retailer CVS is selling a generic alternative to Mylan’s EpiPen autoinjector. The price is about one-sixth of the cost of the name brand product.
ABC News reported:
The drugstore chain says it will charge $109.99 for a two-pack of the authorized generic version of Adrenaclick, a lesser-known treatment compared to EpiPen, which can cost more than $600..The [generic] is now available at all CVS stores. The chain runs about 9,600 retail pharmacies in the United States, including several locations inside Target stores.
A press release from CVS read, in part:
Become a Ragan Insider member to read this article and all other archived content.
Sign up today
Already a member? Log in here.
Learn more about Ragan Insider.
